# Bipar Sciences

**Canonical:** https://apis.io/providers/bipar-sciences/  
**APIs profiled:** 0

BiPar Sciences was a Brisbane, California biopharmaceutical company developing a tumor-selective class of PARP (poly ADP-ribose polymerase) inhibitors for cancer therapy. Its lead candidate, BSI-201 (iniparib), was in mid-stage trials for advanced breast, ovarian, and other tumors. Backed by Canaan Partners, Vulcan Capital, PolyTechnos, Asset Management Company, and Quantum Technology Partners, BiPar was acquired by Sanofi-Aventis for roughly $500 million in April 2009 and no longer operates as an independent company. It was surfaced as a Canaan Partners portfolio company and added to the API Evangelist network as a stub; enrichment finds no public developer or API surface.

## Kin Score — 2.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biopharmaceutical, Oncology, Pharmaceuticals, PARP Inhibitors, Clinical Trials, Acquired, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/bipar-sciences/). Scores are computed from the provider's own public artifacts under a published rubric.